Results 81 to 90 of about 1,406,780 (315)

Cardiovascular adverse events of ibrutinib [PDF]

Blood, 2019
In this issue of Blood, Dickerson et al report on the increased incidence and worsening severity of hypertension and its association with cardiovascular outcomes in 562 patients treated with ibrutinib for B-cell malignancies.
openaire   +2 more sources

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Using an e-Delphi consensus technique to develop the Stressful Adverse Veterinary Events Support (SAVES) Framework

Co-ordinated approaches to supporting veterinary practitioners in relation to adverse events are needed to mitigate associated practitioner stress and to prevent future occurrence.
Brennan, Marnie L, Gibson, Julie, White, Kate   +2 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Blunt splenic injury: are early adverse events related to trauma, nonoperative management, or surgery? [PDF]

, 2015
International audiencePURPOSE:We aimed to compare clinical outcomes and early adverse events of operative management (OM), nonoperative management (NOM), and NOM with splenic artery embolization (SAE) in blunt splenic injury (BSI) and identify the ...
Rodiere, Mathieu, Gilbert Ferretti, Christian Sengel, Thony, Frédéric, Mathieu Rodiere, Bricault, Ivan, Broux, Christophe, Ivan Bricault, Boussat, Bastien, Arvieux, Catherine, Julien Frandon, Frédéric Thony, Frandon, Julien, Sengel, Christian, Christophe Broux, Anne Vendrell, Bastien Boussat, Vendrell, Anne, Ferretti, Gilbert, R., Ferretti, Gilbert,, Catherine Arvieux   +20 more
core   +1 more source

Hallucination: A rare complication of levetiracetam theraphy

İstanbul Kuzey Klinikleri, 2017
Levetiracetam is a new antiepileptic drug. In addition to epilepsy, it is also used for treating anxiety disorders and dystonia as well as tardive dyskinesia associated with the use of levodopa and neuroleptic drugs.
Seher Erdogan, Mehmet Bosnak
doaj   +1 more source

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

FEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen, Qianqian Cui, Zhongyun Lan, Yingjun Wang, Shuaiying Zhao, Wenxuan Feng, Yunfeng Liu, Qiting Huang, Dongna Zhang, Jianfeng Xu   +9 more
wiley   +1 more source

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

Cancer Management and Research, 2019
Helei Hou,* Dantong Sun,* Kewei Liu, Man Jiang, Dong Liu, Jingjuan Zhu, Na Zhou, Jing Cong, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People’s Republic of China*These ...
Hou H, Sun D, Liu K, Jiang M, Liu D, Zhu J, Zhou N, Cong J, Zhang X   +8 more
doaj  

Adverse events and in-hospital mortality: an analysis of all deaths in a Norwegian health trust during 2011

BMC Health Services Research, 2017
Background The estimated number of in-hospitals deaths due to adverse events is often different when using data from deceased patients compared with that of a population experiencing adverse events.
Hans Flaatten, Guttorm Brattebø, Bjørn Alme, Kjersti Berge, Jan H. Rosland, Asgaut Viste, Bjørn Bertelsen, Stig Harthug, Sidsel Aardal   +8 more
doaj   +1 more source

Combined 5‐aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells

FEBS Open Bio, EarlyView.
5‐Aminolevulinic acid combined with ferric ammonium citrate (5‐ALA/FAC) stimulates dermal papilla cell activity and promotes hair follicle growth. The treatment enhances ERK and AKT signaling, increases hair‐inductive gene expression, and restores dermal papilla function suppressed by dihydrotestosterone and oxidative stress, resulting in enhanced hair
Han‐Wook Ryu, Eok‐Soo Oh, Sewoon Kim
wiley   +1 more source